ResMed Financial Statements
NYSE: RMDHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ResMed revenue and earnings
In fiscal 2026, ResMed generated $5.65 billion in revenue, up 9.9% from fiscal 2025, its 17th consecutive year of revenue growth. Net income was $1.52 billion (+8.8% year over year), for a net margin of 26.9% versus a median of 21.8% in the prior 5 years. Gross margin was 61.1% (up from 59.4%) and operating margin 33.4%.
Diluted earnings per share came in at $10.43, up from $9.51. Over the last 5 fiscal years, RMD's revenue has grown at a 12.1% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
ResMed income statement (annual)
| Fiscal year (USD) | FY 20262026-06-30 | FY 20252025-06-30 | FY 20242024-06-30 | FY 20232023-06-30 | FY 20222022-06-30 | FY 20212021-06-30 | FY 20202020-06-30 | FY 20192019-06-30 | FY 20182018-06-30 | FY 20172017-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.65B | 5.15B | 4.69B | 4.22B | 3.58B | 3.20B | 2.96B | 2.61B | 2.34B | 2.07B |
| Revenue growth (YoY) | +9.85% | +9.84% | +10.95% | +18.02% | +11.93% | +8.11% | +13.44% | +11.38% | +13.23% | +12.40% |
| Cost of Revenue | 2.20B | 2.09B | 2.03B | 1.87B | 1.55B | 1.36B | 1.24B | 1.11B | 1.01B | 864.99M |
| Gross Profit | 3.45B | 3.05B | 2.66B | 2.36B | 2.02B | 1.84B | 1.72B | 1.49B | 1.33B | 1.20B |
| Operating Expenses | 1.57B | 1.37B | 1.34B | 1.22B | 1.02B | 935.42M | 908.13M | 914.81M | 793.07M | 775.95M |
| Research & Development | 378.29M | 331.28M | 307.52M | 287.64M | 253.57M | 225.28M | 201.95M | 180.65M | 155.15M | 144.47M |
| Selling, General & Admin | 1.12B | 993.05M | 917.14M | 874.00M | 737.51M | 670.39M | 676.69M | 645.01M | 600.37M | 553.97M |
| Operating Income | 1.89B | 1.69B | 1.32B | 1.13B | 1.00B | 903.68M | 809.66M | 579.26M | 541.83M | 425.80M |
| Interest Expense | — | — | — | — | — | 23.99M | 40.38M | 36.16M | 28.36M | 28.24M |
| Other Income (Expense) | 32.70M | -7.80M | -55.09M | -30.21M | -39.80M | -20.02M | -76.57M | -60.42M | -20.52M | -7.05M |
| Pretax Income | 1.92B | 1.68B | 1.26B | 1.10B | 960.48M | 883.66M | 733.09M | 518.85M | 521.31M | 418.74M |
| Income Tax | 396.12M | 276.84M | 243.85M | 204.11M | 181.05M | 409.16M | 111.41M | 114.25M | 205.72M | 76.46M |
| Net Income | 1.52B | 1.40B | 1.02B | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M | 315.59M | 342.28M |
| Net Income growth (YoY) | +8.75% | +37.20% | +13.75% | +15.15% | +64.26% | -23.67% | +53.65% | +28.20% | -7.80% | -2.87% |
| EPS (Basic) | 10.47 | 9.55 | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 | 2.42 |
| EPS (Diluted) | 10.43 | 9.51 | 6.92 | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 | 2.40 |
| Shares Outstanding (Basic) | 145.52M | 146.72M | 147.02M | 146.76M | 146.07M | 145.31M | 144.34M | 143.11M | 142.76M | 141.36M |
| Shares Outstanding (Diluted) | 146.05M | 147.34M | 147.55M | 147.46M | 147.04M | 146.45M | 145.65M | 144.48M | 143.99M | 142.45M |
| EBITDA | 2.09B | 1.88B | 1.50B | 1.30B | 1.16B | 1.06B | 964.51M | 730.06M | 661.79M | 537.96M |
| Gross Margin | 61.06% | 59.36% | 56.67% | 55.78% | 56.57% | 57.53% | 58.09% | 57.32% | 57.04% | 58.15% |
| Operating Margin | 33.37% | 32.75% | 28.17% | 26.80% | 27.96% | 28.27% | 27.38% | 22.22% | 23.15% | 20.60% |
| Net Margin | 26.94% | 27.22% | 21.79% | 21.25% | 21.78% | 14.84% | 21.02% | 15.52% | 13.49% | 16.56% |
This table shows 10 annual periods of ResMed's income statement, from FY 2026 back to FY 2017, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RMD's reporting calendar. What is a income statement?